R
Rafal Wojciechowski
Publications - 1
Citations - 214
Rafal Wojciechowski is an academic researcher. The author has contributed to research in topics: Placebo-controlled study & Ixekizumab. The author has an hindex of 1, co-authored 1 publications receiving 146 citations.
Papers
More filters
Journal ArticleDOI
Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial
Désirée van der Heijde,James Cheng-Chung Wei,Maxime Dougados,Philip J. Mease,Atul Deodhar,Walter P. Maksymowych,Filip Van den Bosch,Joachim Sieper,Tetsuya Tomita,Robert Landewé,Fangyi Zhao,Eswar Krishnan,David H. Adams,Beth A. Pangallo,Hilde Carlier,Melvin Churchill,Kathleen P. Flint,Geoffrey Gladstein,Maria Greenwald,Mary P. Howell,Akgun Ince,Jeffrey L. Kaine,Daksha Mehta,Eric A. Peters,Roel Querubin,John D. Reveille,Richard Roseff,Roger J. Diegel,Christine Thai,Louis Bessette,Frederic Morin,Proton Rahman,Aaron Alejandro Barrera Rodriguez,Fidencio Cons-Molina,Sergio Duran Barragan,Cassandra M. Skinner,Cesar Francisco Pacheco Tena,Cesar Ricardo Ramos Remus,Juan Cruz Rizo Rodriguez,Seung-Jae Hong,Yeon-Ah Lee,Ji Hyeon Ju,Seong Wook Kang,Tae-Hwan Kim,Chang Keun Lee,Eun Bong Lee,Sang-Heon Lee,Min Chan Park,Kichul Shin,Sang-Hoon Lee,Hung-An Chen,Ying-Chou Chen,Song-Chou Hsieh,Joung-Liang Lan,Zdenek Dvorak,Radka Moravcova,Martina Malcova,Yoshinori Taniguchi,Mitsumasa Kishimoto,Kurisu Tada,Hiroaki Dobashi,Kentaro Inui,Yukitaka Ueki,Yoshifuji Matsumoto,Yoshinobu Koyama,Kazuhiro Hatta,Tatsuya Atsumi,Hitoshi Goto,Kiyoshi Matsui,Yuya Takakubo,Gunther Neeck,Denis Poddubnyy,Andrea Rubbert-Roth,Malgorzata Szymanska,Tomasz Blicharski,Anna Dudek,Artur Racewicz,Rafal Wojciechowski,Marleen G H van de Sande,Ed Griep,Michael T. Nurmohamed,Galina Matsievskaya,Evgeniya Shmidt,Marina Stanislav,Sergey Yakushin,Olga Ershova,A P Rebrov,Tibor Balazs,Regina Cseuz,E. Drescher,Gyula Poor +90 more
TL;DR: Each dosing regimen of ixekizumab was superior to placebo for improving radiographic axial spondyloarthritis signs and symptoms in patients not previously treated with bDMARDs; the safety profile was consistent with previous indications of IXekzumab.